Physiogenomic analysis of CYP450 drug metabolism correlates dyslipidemia with pharmacogenetic functional status in psychiatric patients

Biomarkers in Medicine

Volumn 5, Issue 4, 2011, Pages 439-449

  Ruao, Gualberto ^a,b   Villagra, David ^a   Szarek, Bonnie ^b   Windemuth, Andreas ^a,b   Kocherla, Mohan ^a,b   Gorowski, Krystyna ^a   Berrezueta, Christopher ^a   Schwartz, Harold I ^b   Goethe, John ^b  

^a Genomas Inc   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

combinatory genotypes; CYP450; dyslipidemia; physiogenomics; psychopharmacology

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ARIPIPRAZOLE; CITALOPRAM; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; GLITAZONE DERIVATIVE; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMOTRIGINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SERTRALINE; STATIN; TOPIRAMATE; TRIACYLGLYCEROL; VALPROATE SEMISODIUM;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; CONVULSION; DEPRESSION; DRUG METABOLISM; DYSLIPIDEMIA; ENZYME SPECIFICITY; ETHNICITY; FEMALE; GENOMICS; GENOTYPE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; METABOLIC DISORDER; METABOLIC SYNDROME X; MULTIGENE FAMILY; NEUROMUSCULAR DISEASE; PHARMACOGENETICS; PHYSIOGENOMICS; PSYCHOPHARMACOLOGY; PSYCHOSIS; RISK ASSESSMENT; SIDE EFFECT; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL MARKERS; BODY MASS INDEX; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEPRESSIVE DISORDER, MAJOR; DYSLIPIDEMIAS; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHOTROPIC DRUGS; RISK FACTORS; TRIGLYCERIDES;

EID: 80052071529     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.11.33     Document Type: Article

References (48)

1. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19(Suppl. 1), 1-93 (2005). (Pubitemid 40677047)
2. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can. J. Psychiatry 51(8), 480-491 (2006). (Pubitemid 44166336)
3. Goethe JW, Szarek BL, Woolley SB, Caley CF. Metabolic abnormalities in psychiatric inpatients. Presented at: American Psychiatric Association meeting. San Diego, CA, USA, 19-24 May 2007.
4. Goethe J W. Metabolic syndrome in psychiatric inpatients receiving antipsychotics. Presented at: American Psychiatric Association meeting. Atlanta, GA, USA, 21-26 May 2005.
5. Goethe JW, Szarek BL, Caley CF et al. Signs and symptoms associated with the metabolic syndrome in psychiatric inpatients receiving antipsychotics: a retrospective chart review. J. Clin. Psychiatry 68(1), 22-28 (2007). (Pubitemid 46220120)
6. Kinder LS, Carnethon MR, Palaniappan LP et al. Depression and the metabolic syndrome in young adults: fndings from the Third National Health and Nutrition Examination Survey. Psychosom. Med. 66(3), 316-322 (2004). (Pubitemid 38668398)
7. Heiskanen TH, Niskanen LK, Hintikka JJ et al. Metabolic syndrome and depression: a cross-sectional analysis. J. Clin. Psychiatry 67(9), 1422-1427 (2006). (Pubitemid 44583390)
8. Goethe JW, Szarek BL, Caley CF: Metabolic syndrome in psychiatric inpatients treated for depression. In: Metabolic Effects of Psychotropic Drugs. Thakore J, Leonard B (Eds). Karger, Basel, Switzerland, 90-104, 2009.
9. Brown ES, Varghese FP, McEwen BS. Association of depression with medical illness: does cortisol play a role? Biol. Psychiatry 55(1), 1-9 (2004). (Pubitemid 38045427)
10. Goethe JW, Szarek BL, Caley CF. Metabolic syndrome and depression: a review. Depression: Mind and Body 3(4), 138-149 (2008).
11. Katon WJ, Lin EH, Russo J et al. Cardiac risk factors in patients with diabetes mellitus and major depression. J. Gen. Intern. Med. 19(12), 1192-1199 (2004). (Pubitemid 40041383)
12. Musselman DL, Betan E, Larsen H et al. Relationship of depression to diabetes Types 1 and 2: epidemiology, biology, and treatment. Biol. Psychiatry 54(3), 317-329 (2003). (Pubitemid 37267861)
13. Lee ES, Kim YH, Beck SH et al. Depressive mood and abdominal fat distribution in overweight premenopausal women. Obes. Res. 13(2), 320-325 (2005).
14. Ohayon MM. Epidemiology of depression and its treatment in the general population. J. Psychiatr. Res. 41(3-4), 207-213 (2007). (Pubitemid 44855001)
15. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: fndings from the third National Health and Nutrition Examination Survey. JAMA 287(3), 356-359 (2002). (Pubitemid 34251969)
16. Almeida OP, Flicker L, Norman P et al. Association of cardiovascular risk factors and disease with depression in later life. Am. J. Geriatr. Psychiatry 15(6), 506-513 (2007).
17. Scalco AZ, Scalco MZ, Azul JB et al. Hypertension and depression. Clinics (Sao Paulo) 60(3), 241-250 (2005).
18. Sonawalla SB, Papakostas GI, Petersen TJ et al. Elevated cholesterol levels associated with nonresponse to fuoxetine treatment in major depressive disorder. Psychosomatics 43(4), 310-316 (2002).
19. Papakostas GI, Petersen T, Sonawalla SB et al. Serum cholesterol in treatment-resistant depression. Neuropsychobiology 47(3), 146-151 (2003). (Pubitemid 36676978)
20. Kopf D, Westphal S, Luley CW et al. Lipid metabolism and insulin resistance in depressed patients: signifcance of weight, hypercortisolism, and antidepressant treatment. J. Clin. Psychopharmacol. 24(5), 527-531 (2004). (Pubitemid 39274207)
21. Raeder MB, Bjelland I, Emil VS et al. Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: the Hordaland Health Study. J. Clin. Psychiatry 67(12), 1974-1982 (2006). (Pubitemid 46048196)
22. Lara N, Baker GB, Archer SL et al. Increased cholesterol levels during paroxetine administration in healthy men. J. Clin. Psychiatry 64(12), 1455-1459 (2003). (Pubitemid 41270104)
23. Bailey DL, Le Melledo JM. Effects of selective serotonin reuptake inhibitors on cholesterol levels in patients with panic disorder. J. Clin. Psychopharmacol. 23(3), 317-319 (2003). (Pubitemid 36807801)
24. Peter H, Tabrizian S, Hand I. Serum cholesterol in patients with obsessive compulsive disorder during treatment with behavior therapy and SSRI or placebo. Int. J. Psychiatry Med. 30(1), 27-39 (2000). (Pubitemid 30439393)
25. Stimmel GL, Dopheide JA, Stahl SM. Mirtazapine: an antidepressant with noradrenergic and specifc serotonergic effects. Pharmacotherapy 17(1), 10-21 (1997). (Pubitemid 27057115)
26. Hardy T, Sachson R, Shen S et al. Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care 30(1), 21-26 (2007). (Pubitemid 46052495)
27. Montgomery SA. Safety of mirtazapine: a review. Int. Clin. Psychopharmacol. 10(Suppl. 4), 37-45 (1995). (Pubitemid 26058318)
28. Laika B, Leucht S, Heres S et al. Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening? Pharmacogenomics J. 9(6), 395-403 (2009).
29. Ingelman-Sundberg M, Rodriguez-Antona C. Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 360(1460), 1563-1570 (2005).
30. Ruaño G, Villagra D, Rahim U-S et al. Increased carrier prevalence of defcient CYP2C9, CYP2C19 and CYP2D6 alleles in depressed patients referred to a tertiary psychiatric hospital. Personalized Medicine 5(6), 579-587 (2008).
31. Black JL, III, O'Kane DJ, Mrazek DA. The impact of CYP allelic variation on antidepressant metabolism: a review. Expert Opin. Drug Metab. Toxicol. 3(1), 21-31 (2007). (Pubitemid 47307454)
32. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical signifcance: part II. Clin. Pharmacokinet. 48(12), 761-804 (2009).
33. Ruaño G, Blair CL, Bower B et al. Somatic complications of psychotropic medications in a patient with multiple CYP2 drug metabolism defciencies. Conn. Med. 71(4), 197-200 (2007).
34. Kirchheiner J, Rodriguez-Antona C. Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders. CNS Drugs 23(3), 181-191 (2009).
35. Kirchheiner J, Nickchen K, Bauer M et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 9(5), 442-473 (2004). (Pubitemid 38903502)
36. Kootstra-Ros JE, Van Weelden MJ, Hinrichs JW et al. Therapeutic drug monitoring of antidepressants and cytochrome p450 genotyping in general practice. J. Clin. Pharmacol. 46(11), 1320-1327 (2006). (Pubitemid 44564361)
37. Ruaño G, Windemuth A, Holford T. Physiogenomics: integrating systems engineering and nanotechnology for personalized medicine. In: The Biomedical Engineering Handbook (3rd Edition). Bronzino JD (Ed.). CRC Press, FL, USA (2005).
38. Villagra D, Goethe J, Schwartz HI et al. Novel drug metabolism indices for pharmacogenetic functional status based on combinatory genotyping of CYP2C9, CYP2C19 and CYP2D6 genes. Biomark. Med. 5(4), 427-438 (2011).
39. Ruaño G, Thompson PD, Windemuth A et al. Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis. Pharmacogenomics 6(8), 865-872 (2005). (Pubitemid 41724360)
40. Ruaño G, Thompson PD, Windemuth A et al. Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle Nerve 36(3), 329-335 (2007). (Pubitemid 47326011)
41. Ruaño G, Goethe JW, Caley C et al. Physiogenomic comparison of weight profles of olanzapine-and risperidone-treated patients. Mol. Psychiatry 12, 474-482 (2007). (Pubitemid 46652457)
42. Ruaño G, Bernene J, Windemuth A et al. Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone. Clin. Chim. Acta 400(1-2), 48-55 (2009).
43. Ruaño G, Windemuth A, Kocherla M et al. Physiogenomic analysis of weight loss induced by dietary carbohydrate restriction. Nutr. Metab. (Lond.) 3, 20 (2006).
44. Seip RL, Volek JS, Windemuth A et al. Physiogenomic comparison of human fat loss in response to diets restrictive of carbohydrate or fat. Nutr. Metab. (Lond.) 5, 4 (2008).
45. Drug Information Handbook: A Comprehensive Resource for All Clinicians and Healthcare Professionals. Lacy CF, Armstrong LL, Goldman MP, Lance LL (Eds). Lexi-Comp, OH, USA (2009).
46. Gordon J, Merante F, Weiss S, Zastawny R. Pharmacogenetic P-450 screening using the tag-it universal bead-based array platform. In: Pharmacogenomics and Proteomics: Enabling the Practice of Personalized Medicine. Wong SH, Linder MW, Valdes R Jr (Eds). AAC Press, Washington DC, USA (2006).
47. Cleveland WS, Devlin SJ. Locally weighted regression: an approach to regression analysis by local ftting. J. Am. Stat. Assoc. 83(403), 596-610 (1988).
48. Kahn R, Buse J, Ferrannini E et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28(9), 2289-2304 (2005). (Pubitemid 41242486)